Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am playing the part of the savvy investor GLTA
Check out PapaGallos restaurant while your there. You are entertained by tropical birds at most tables perched near by.
Maybe Mr. Dart will enjoying some lobster at a nearby table.
Prepare to bring some coin it is a little expensive.
MD honest efforts to get the word out never hurt us. Thanks
AstraZeneca lends its oncology star to Celgene and recruits Innate in a PD-L1 deal spree
April 24, 2015 | By Damian Garde
AstraZeneca ($AZN) signed a pair of agreements centered on its most prized cancer therapy, selling a stake to the hematology experts at Celgene ($CELG) and buying the rights to a complementary treatment from Innate Pharma.
The company's treatment, MEDI4736, is an antibody designed to block an immune checkpoint called PD-L1 to cut the brakes on the immune system and allow the body's natural defenses to attack tumors. And, in a pair of deals worth nearly $1.8 billion, AstraZeneca is broadening its development program and bringing in a pair of new collaborators.
AstraZeneca is already pushing the antibody forward in lung and other cancer..................................
The pair of pacts comes just a day after AstraZeneca partnered up with Juno Therapeutics ($JUNO) to test that company's pioneering CAR-T technology with MEDI4736 in blood cancers. Like its rivals Merck ($MRK) and Bristol-Myers Squibb ($BMY), AstraZeneca believes the brightest future for PD-1 and PD-L1 therapies could be in tandem with other marketed or in-development treatments, and the company is widening its stable of partners in hopes of eventually getting MEDI4736 approved for a host of cancers.
Analysts figure the whole class of checkpoint inhibitors can top out at about $35 billion a year, and AstraZeneca says its contender can eventually bring in $6.5 billion in peak annual sales.
"We believe that combination therapy in immuno-oncology has the potential to be one of the most effective ways of treating cancer and that by targeting both innate and acquired immunity we have the opportunity to deliver important clinical benefit to patients across a range of cancers," AstraZeneca CEO Pascal Soriot said.......
Well my son has had several conversations with Brad Loncar about many stocks but also PPHM. He has had those conversations before on PPHM with other folks.
I agree the possibility does exist for early results. Especially as you said if the enrollment is trending well. Partnerships always a possibility during Phase 3 trials as we know.
There is definitely a possibility of SUNRISE trial being halted in 2015.
It ALL has to do with how fast enrollment is trending, if we have first look in by end of May, we should see full enrollment by October and 2nd look in with six weeks of the full enrollment PR.
I'm very optimistic about SUNRISE and bavituximab.
But remember as Volgoat said we may see bavituximab approved for melanoma first.
Approval or trial halt is NOT my goal for PPHM in 2015, my goal is a true partner. BMY is my guess then possibly Roche then Abbvie/Calico.
I've never been more secure about my investment in PPHM then I am today. Waiting is hard, but patience I have learned. It will make my goal of early retirement and time with my children that more precious.
Approval will assure great combo treatments.
Please note I believe the PD-1 class of drugs to be an essential part of the cure for cancer and as a practitioner want expanded label ASAP. Bavituximab will make PD-1 non responders into responders. A perfect one two punch.
CP excellent recap. Thanks.
EB & Goodplenty100 Holding and buying more to. We have over 240,000 shares in the family now. Exciting times. Bavi is here to stay and will help folks out.
EBS Then again it may not be what you think.
Could be Opdivo mos comes in around 8.2-8.7 range on ASCO PR
and bavi mos comes in later around 10-13.3 range. Will see.
Got to wait for the NUMBERS
Ok that was what I have heard as possible timeframe. Thanks.
Anybody. How do you see this lining up below?
Docetaxel is SOC with MOS around 5.6 months for the moment although that will change very soon.
Do you think checkmate 057 will have a MOS around 8.2 months in this disease indication as well?
Bava perhaps 13 months?
EXwannabe-When do you expect a read out/PR on MOS for CheckMate - 057) since SUNRISE is in this disease indication I am curious of MOS endpoint?
The phase III study evaluated Opdivo in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) in comparison to docetaxel. The study showed superior overall survival in patients receiving Opdivo as compared to the control arm.
jbainseky Your playing my kind of music. Bring out the band cause we are going on a march in the "NEAR TERM".
md1225 - I don't believe we will hear of a partnership until approval is all but certain, that is SUNRISE is stopped. Furthermore, I expect the PPS to rise quickly to between $20 and $30 per share on the news of the trial being stopped. That figure is based on estimated $1B/year sales with an industry nominal standard of 6X revenue for market cap, which means between 200 and 300 milion shares outstanding at the time, including PPHMP conversion. In rough numbers, that gives PPHM another 50M shares to dilute via the ATM/PPHMP.
That is only the first "run" and will give institutions plenty of time to accumulate and get retail out of the way for the real incerease as BAVI is used for multiple indications etc.
JMHO
FFTT
JBAIN
BCS thanks for correction. I got this from SEC Filing SCHEDULE 13G/A
KENNETH B. DART
02/13/2015
COMMON STOCK, $0.001 PAR VALUE PER SHARE
CUSIP No. 713661304
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
EASTERN CAPITAL LIMITED
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,921,760
Good or bad for PPHM??
Kenneth B. Dart
Dart owns 9,921,760 shares (the family)
5.4% give or take
Old article from Motley:
May 09, 2010
Heya Fools,
Several weeks ago S.C. and I were talking about different companies that we were looking at purchasing stock in. S.C. told me that he liked SPPI, primarily because of insider buying and a giant block of stock being purchased by Kenneth Dart.
I understood the insider buyer aspect, but when I asked who Kenneth Dart was he said I should look him up.
This guy is a serious operator with a brass pair. He almost never loses. He's sometimes called an industrialist, financier, vulture capitalist and sharehold rights activist. He owns an armored yacht with antiaircraft guns mounted on it. That is awesome.
He is the CEO of the Dart Container Corporation, the inventors of the styrofoam cup. They never patented the machine and process because they didn't want competitors to be able to copy their design. To this day only a few highly trusted employees of the Dart Container Company are allowed to see the machinery itself.
In 1994 Kenneth and his Robert C. Dart brother moved to the Cayman Islands and Belize and renounced their U.S. citizenship. They did this to avoid paying taxes, a noble goal. Kenneth bought himself dual citizenship in Ireland and Belize. He then paid Belize to appoint him as their ambassador to the United States, in an embassy a couple of miles away from the home in Florida that Ken's wife continues to live in.
Bill Clinton was like "No ******* way!".
Kenneth is an astute investor. He bought distressed sovereign debt from Argentina for 20 cents on the dollar, then forced Argentina to pay him about $20 for every man woman and child in the country. He made similar moves with the debts of Russia, Brazil, Ecuador, and Turkey. Couldn't have happened to a nicer bunch of countries in my opinion.
Ken also invests in biotech. He bought 8.5% of CVT, shortly before they were bought out in a nasty bidding war between Astellas and Gilead culminating in the March 12th 2009 buyout for $1.4 billion.
Kenneth recently purchased 8% of SPPI through his hedge fund, Eastern Capital LTD. Eastern really isn't a hedge fund, it is all Dart family money. I can't buy up debt of struggling countries and strongarm them into paying me while sitting off the Caymans on my armored yacht, but I can follow Ken into this trade.
I have links to more info about Ken and I write a little about the JPMorgan investigation here.
Stay Foolish,
DT
CB This one got by me. Could you provide the source for the statement below. Thanks
Clearly CSM lawyers not worried about ELD as they turned down a $4m settlement offer by ppphm. If they thought there was any chance of a huge verdict against them they would have settled for the $4m policy limits.
Thanks MD for getting the word out through your article. I know of three people that have bought over 180,000 in my circle of influence recently and the article figured in their decision. GLTA
TOG
Need ducks lined up first. Manufacturing capability first, then...
Quote:
--------------------------------------------------------------------------------
Quite possible that the buildout has something to do with it but if they had BTD you would think its a material event that needs to be announced.
--------------------------------------------------------------------------------
Unless it is contingent. Need that paper (faxed) in hand before they can consider it material. Plus, it keeps from any possible sabotage to the Avid buildout.
BIO If SUNRISE approaches or surpasses 100% MOS which I believe it will. That'll rattle the cages and the LOOF rocket will blast off.
Why docetaxel being generic is a huge plus for BAVI - once SUNRISE is successful and the product is approved.
Quote:
--------------------------------------------------------------------------------
Roy Friedman ?@DewDiligence · 1m1 minute ago
The US list price for a year of Opdivo/Yervoy combination treatment is almost $300K. One might call that "cumulative financial toxicity."
In Yahoo
Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.
This where bavi could help
In addition, a fair number of patients in these various clinical trials didn't show any meaningful clinical benefit from either Opdivo or Keytruda. So, the picture that's starting to emerge is that some patients respond extremely well to PD-1 inhibitors, whereas others, maybe even the majority, simply aren't good candidates for this new class of drugs.
Thanks Wook
Quote:
Steven Worsely...from what I gather...back log are signed contracts and the tip of the ice burg.
Avid Expansion is a no frills get it built with production capacity in mind and costs are much more managed for optimum output for the price. Really gave Steve King props for his vision on this topic. Met SK as well, really exudes confidence. Worsely went on about business like Dr. Garnick went on about the BLA.
Worsley has 12 BPs as most practical big names to partner with on an oncology basis, no per indication, entire platform. Regional yes but no individual indications...ie liver or lung. The whole enchilada.He has a Fav 4 that seem to be most advanced ie...multiple meetings. Approval need not be the key as translational and secondary endpoints are noted as potential deal maker data points.
Biomarkers and secondary endpoints are a focus concerning negotiable data.
Opdivo not really an issue unless a patient can pay off label out of pocket for next 4-6 months minimum and Sunrise remains on track to be fully enrolled.
Gotta read a book now to the kiddos.
wook
Couch when Bavi is approved the cloud lifts and the price soars. Glad I am in now and still adding shares. GLTA
GEO I believe Sunrise will surprise us. GLTA
Did not stipulate that. EOM
Now Sunrise needs 100% MOS to be assured approval?
djohn Obviously there are similarities and differences between these trials to be sure. If Sunrise MOS hits the loftier numbers approaching 100% MOS over present SOC with Doce approval assured.
Even if MOS around 50% expect approval as a combo therapy due to efficacy and data from other combo trials that are developing nicely.
CP I wander what percentage of patients responded in the BMY/OPTIVO trial for non-squamous and could Bavi improve this.
CP I agree with your analogy.
Not sure at all. Doce+Bavi may hurt Optivo/BMY if it performs as in the PII because that combo would for sure beat Optivo.
Now if Optivo beats Doce big time, SUNRISE will still get approved because it compares with Doce alone and Bavi can combine with Optivo as well.
Every next clinical trial with bavi, will be FAST and probably a single-track based on BTD's.
Again, the more of those drugs there are to save people with cancer the more opportunity for PPHM to combine with. SUNRISE is just the door opener and isn't influenced by any other approval since then.
sunstar Thanks for perspective and overview.
Looking forward to when this whole CSM trial fiasco is in the rear view mirror and the cloud finally lifts. The science emerges with FDA approval and the conversations and focus shifts back to all of the potential possibilities of treatment with BAVI.
What a read. Would not want to be in her shoes or CSM'S position.
BIO Big clue on future dealings with Avid.
Class 10,000 ISO 7
Good points made CP
BIO good summarization of a POST 2012 shareholder's view
IMO - the lack of significant institutional holding is because "everyone" is v=waiting for validation of BAVI - given what happened with the phase II NSCLC data and the controversy surrounding that. That validation will come either from an external partner, or more likely will have to come from the SUNRISE trial results. If the results are good, the price will take care of itself even with the existing BoD. If the results are negative, even having every CEO of the top 20 biotechs on the BoD will not help. At this point it is really as simple as that.
Everyone can bellyache till the cows come home and it isn't going to change this reality.
TGIF. Cheers.
AF Couldn't happen to a nicer guy. What goes around comes around.
CP well articulated. Pardon my one-liner.
[url]I am not waiting to be congratulated, neither do I want to convince anybody not even myself because I am already convinced.
But I like to defend my investment, stand behind it and have continuous reality checks by means of all kinds of opinions and statements on this board that I can then check and decide whether I am still good or whether an argument is brought to the table that would force me to re-evaluate my PPHM investment.
And yes, if I think a statement is light, not funded or substantiated etc I react, at the risk of being wrong by times but ALWAYS with fact or reasoning, assumption or speculation provided. NEVER cheap one-liners or sentiment cheer-leading.
[/url][tag]insert-text-here[/tag]
Hence the expansion of Avid decision.
over 25 mil shorted too.
BLZ-100 is the first product candidate developed from the Tumor Paint technology platform. Tumor Paint technology is designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling better detection and more complete and precise surgical removal of cancer, and has potential applications in a broad array of solid tumor cancers. BLZ-100 is a combination of a targeting peptide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. BLZ-100 is under development for cancer surgery in multiple solid tumor types.
Yes, I recall. Thanks.